Quest Diagnostics Incorporated Financial Statements (DGX) |
||||||||||
Quest Diagnostics Incorporatedsmart-lab.ru | % | 2020 | 2021 | 2022 | 2022 | 2023 | LTM ? | |||
---|---|---|---|---|---|---|---|---|---|---|
Report date | 22.02.2021 | 28.02.2022 | 31.12.2022 | 21.02.2023 | 22.02.2024 | 23.10.2024 | ||||
Currency | USD | USD | USD | USD | USD | USD | ||||
Financial report URL | ||||||||||
Revenue, bln rub | ? | 9 437 | 10 788 | 9 883 | 9 883 | 9 252 | 9 770 | |||
Operating Income, bln rub | 1 971 | 2 381 | 1 428 | 1 428 | 1 262 | 1 351 | ||||
EBITDA, bln rub | ? | 2 411 | 3 159 | 1 785 | 1 820 | 1 732 | 1 143 | |||
Net profit, bln rub | ? | 1 431 | 1 995 | 946.0 | 946.0 | 854.0 | 1 325 | |||
OCF, bln rub | ? | 2 005 | 2 233 | 1 718 | 1 718 | 1 272 | 1 072 | |||
CAPEX, bln rub | ? | 418.0 | 403.0 | 404.0 | 404.0 | 408.0 | 394.0 | |||
FCF, bln rub | ? | 1 587 | 1 830 | 1 314 | 1 314 | 864.0 | 1 070 | |||
Dividend payout, bln rub | 297.0 | 309.0 | 305.0 | 305.0 | 314.0 | 252.0 | ||||
Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
Dividend payout ratio, % | 20.8% | 15.5% | 32.2% | 32.2% | 36.8% | 19.0% | ||||
OPEX, bln rub | 1 662 | 1 828 | 1 874 | 2 005 | 1 610 | 1 765 | ||||
Cost of production, bln rub | 5 804 | 6 579 | 0.000 | 6 450 | 6 291 | 8 123 | ||||
R&D, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
Interest expenses, bln rub | 163.0 | 151.0 | 138.0 | 138.0 | 163.0 | 381.0 | ||||
Assets, bln rub | 14 026 | 13 611 | 12 837 | 12 837 | 14 022 | 16 095 | ||||
Net Assets, bln rub | ? | 6 759 | 6 444 | 5 893 | 5 893 | 6 307 | 6 809 | |||
Debt, bln rub | 4 655 | 4 657 | 4 775 | 4 622 | 5 369 | 6 970 | ||||
Cash, bln rub | 1 158 | 872.0 | 315.0 | 315.0 | 686.0 | 764.0 | ||||
Net debt, bln rub | 3 497 | 3 785 | 4 460 | 4 307 | 4 683 | 6 206 | ||||
Ordinary share price, rub | 119.2 | 173.0 | 156.4 | 156.4 | 137.9 | 131.3 | ||||
Number of ordinary shares, mln | 134.0 | 125.0 | 116.0 | 116.0 | 112.0 | 112.0 | ||||
Market cap, bln rub | 15 969 | 21 626 | 18 147 | 18 147 | 15 443 | 14 709 | ||||
EV, bln rub | ? | 19 466 | 25 411 | 22 607 | 22 454 | 20 126 | 20 915 | |||
Book value, bln rub | -1 281 | -1 818 | -2 419 | -2 419 | -2 592 | -3 512 | ||||
EPS, rub | ? | 10.7 | 16.0 | 8.16 | 8.16 | 7.63 | 11.8 | |||
FCF/share, rub | 11.8 | 14.6 | 11.3 | 11.3 | 7.71 | 9.55 | ||||
BV/share, rub | -9.56 | -14.5 | -20.9 | -20.9 | -23.1 | -31.4 | ||||
EBITDA margin, % | ? | 25.5% | 29.3% | 18.1% | 18.4% | 18.7% | 11.7% | |||
Net margin, % | ? | 15.2% | 18.5% | 9.57% | 9.57% | 9.23% | 13.6% | |||
FCF yield, % | ? | 9.94% | 8.46% | 7.24% | 7.24% | 5.59% | 7.27% | |||
ROE, % | ? | 21.2% | 31.0% | 16.1% | 16.1% | 13.5% | 19.5% | |||
ROA, % | ? | 10.2% | 14.7% | 7.37% | 7.37% | 6.09% | 8.23% | |||
P/E | ? | 11.2 | 10.8 | 19.2 | 19.2 | 18.1 | 11.1 | |||
P/FCF | 10.1 | 11.8 | 13.8 | 13.8 | 17.9 | 13.7 | ||||
P/S | ? | 1.69 | 2.00 | 1.84 | 1.84 | 1.67 | 1.51 | |||
P/BV | ? | -12.5 | -11.9 | -7.50 | -7.50 | -5.96 | -4.19 | |||
EV/EBITDA | ? | 8.07 | 8.04 | 12.7 | 12.3 | 11.6 | 18.3 | |||
Debt/EBITDA | 1.45 | 1.20 | 2.50 | 2.37 | 2.70 | 5.43 | ||||
R&D/CAPEX, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
CAPEX/Revenue, % | 4.43% | 3.74% | 4.09% | 4.09% | 4.41% | 4.03% | ||||
Quest Diagnostics Incorporated shareholders |